Inventor · disambiguated record
H. Michael Shepard
Also filed as: SHEPARD H M · SHEPARD H MICHAEL
59 granted patents·35 pending applications·4,362 citations·filing 1987–2025
99Inventor score
Top patents by PatentIndex Score
94 records- 0199US6399063B1Monoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1998·Granted Jun 4, 2002·282 cites·18 claims
- 0299US6387371B1Monoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1999·Granted May 14, 2002·272 cites·14 claims
- 0399US6165464AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1998·Granted Dec 26, 2000·363 cites·11 claims
- 0499US5772997AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1995·Granted Jun 30, 1998·437 cites·13 claims
- 0599US5770195AMonoclonal antibodies directed to the her2 receptorGENENTECH INC·Filed 1995·Granted Jun 23, 1998·492 cites·36 claims
- 0699US5720954AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1995·Granted Feb 24, 1998·328 cites·35 claims
- 0799US5677171AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1994·Granted Oct 14, 1997·924 cites·39 claims
- 0898US11066656B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2020·Granted Jul 20, 2021·30 cites·25 claims
- 0998US11041149B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2020·Granted Jun 22, 2021·32 cites·17 claims
- 1098US10865400B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2016·Granted Dec 15, 2020·25 cites·18 claims
- 1198US6015567AHER2 extracellular domainGENENTECH INC·Filed 1995·Granted Jan 18, 2000·283 cites·26 claims
- 1297US12104185B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Oct 1, 2024·2 cites·11 claims
- 1397US12091692B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2021·Granted Sep 17, 2024·3 cites·40 claims
- 1497US12077791B2PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereofHALOZYME INC·Filed 2023·Granted Sep 3, 2024·1 cites·10 claims
- 1597US12018298B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Jun 25, 2024·1 cites·22 claims
- 1697US11952600B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Apr 9, 2024·2 cites·21 claims
- 1797US9447401B2PH20 polypeptide variants, formulations and uses thereofWEI GE·Filed 2012·Granted Sep 20, 2016·47 cites·49 claims
- 1896US5837520AMethod of purification of viral vectorsCANJI INC·Filed 1995·Granted Nov 17, 1998·170 cites·27 claims
- 1995US6333169B1HER2 extracellular domainGENENTECH INC·Filed 1995·Granted Dec 25, 2001·151 cites·16 claims
- 2094US12264345B1PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Apr 1, 2025·0 cites·17 claims
- 2194US8846034B2Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereofJIANG PING·Filed 2012·Granted Sep 30, 2014·15 cites·58 claims
- 2293US12195773B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Jan 14, 2025·0 cites·15 claims
- 2393US2025051747A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Application pending·0 cites
- 2492US12037618B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2021·Granted Jul 16, 2024·1 cites·40 claims
- 2592US2025154488A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Application pending·0 cites
- 2691US10137104B2Combination therapy with an anti-hyaluronan agent and therapeutic agentHALOZYME INC·Filed 2017·Granted Nov 27, 2018·9 cites·30 claims
- 2791US9913822B2Combination therapy with an anti-hyaluronan agent and therapeutic agentMANEVAL DANIEL C·Filed 2013·Granted Mar 13, 2018·23 cites·35 claims
- 2890US12371685B2PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereofHALOZYME INC·Filed 2023·Granted Jul 29, 2025·0 cites·10 claims
- 2990US12152262B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Nov 26, 2024·0 cites·13 claims
- 3090US6339151B1Enzyme catalyzed therapeutic agentsNEWBIOTICS INC·Filed 1999·Granted Jan 15, 2002·43 cites·9 claims
- 3190US4963354AUse of tumor necrosis factor (TNF) as an adjuvantGENENTECH INC·Filed 1987·Granted Oct 16, 1990·97 cites·8 claims
- 3288US12123035B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 22, 2024·0 cites·34 claims
- 3388US12110520B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 8, 2024·0 cites·35 claims
- 3488US12104184B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 3588US12060590B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Aug 13, 2024·0 cites·35 claims
- 3688US12054758B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Aug 6, 2024·0 cites·40 claims
- 3788US12049652B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Jul 30, 2024·0 cites·40 claims
- 3888US2023287381A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Application pending·0 cites
- 3986US6245750B1Enzyme catalyzed therapeutic agentsNEWBIOTICS INC·Filed 1999·Granted Jun 12, 2001·60 cites·7 claims
- 4083US6683061B1Enzyme catalyzed therapeutic activationNEWBIOTICS INC·Filed 2000·Granted Jan 27, 2004·16 cites·10 claims
- 4182US4808402AMethod and compositions for modulating neovascularizationUNIV NORTHWESTERN·Filed 1987·Granted Feb 28, 1989·131 cites·15 claims
- 4282US2025197835A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4382US2025197832A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4482US2025197834A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4582US2025197833A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 4680US7419968B1Methods for treating therapy-resistant tumorsCELMED ONCOLOGY USA INC·Filed 2000·Granted Sep 2, 2008·9 cites·4 claims
- 4778US7462605B2Phosphoramidate compounds and methods of useCELMED ONCOLOGY USA INC·Filed 2002·Granted Dec 9, 2008·7 cites·28 claims
- 4878US7138388B2Methods to treat autoimmune and inflammatory conditionsCELMED ONCOLOGY USA INC·Filed 2002·Granted Nov 21, 2006·5 cites·2 claims
- 4978US2023203470A1Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using sameHALOZYME INC·Filed 2022·Application pending·0 cites
- 5075US9278124B2Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methodsSHEPARD H MICHAEL·Filed 2013·Granted Mar 8, 2016·3 cites·51 claims
Showing the top 50 of 94 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when H. Michael Shepard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →